Trials2 sources
Monte Rosa shares positive Phase 1 trial data for MRT-8102
The four-week trial of 108 obese individuals at high cardiovascular risk showed sustained NEK7 degradation to counter heart inflammation, the company reports.
News · Trials
News
What companies, regulators and the press said about aging biology this week, in our own words, with the source a tap away.
Yesterday
Thursday 1 October
Trials2 sources
Trevogrumab prevents muscle loss during semaglutide treatment in Phase 2 trial
In an MRI substudy of the COURAGE trial, trevogrumab reduced semaglutide-associated muscle loss by 70 percent during weight reduction.